...
首页> 外文期刊>International journal of colorectal disease. >Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.
【24h】

Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.

机译:舒林酸和菊粉/ VSL#3干预对家族性腺瘤性息肉病患者小袋黏膜和管腔因子的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND/AIM: In order to define future chemoprevention strategies for adenomas or carcinomas in the pouch of patients with familial adenomatous polyposis (FAP), a 4-weeks intervention with (1) sulindac, (2) inulin/VSL#3, and (3) sulindac/inulin/VSL#3 was performed on 17 patients with FAP in a single center intervention study. Primary endpoints were the risk parameters cell proliferation and glutathione S-transferase (GST) detoxification capacity in the pouch mucosa; secondary endpoints were the short chain fatty acid (SCFA) contents, pH, and cytotoxicity of fecal water. METHODS: Before the start and at the end of each 4-week intervention period, six biopsies of the pouch were taken and feces was collected during 24 h. Cell proliferation and GST enzyme activity was assessed in the biopsies and pH, SCFA contents, and cytotoxicity were assessed in the fecal water fraction. The three interventions (sulindac, inulin/VSL#3, sulindac/inulin/VSL#3) were compared with the Mann-Whitney U test. RESULTS: Cell proliferation was lower after sulindac or VSL#3/inulin, the combination treatment with sulindac/inulin/VSL#3 showed the opposite. GST enzyme activity was increased after sulindac or VSL#3/inulin, the combination treatment showed the opposite effect. However, no significance was reached in all these measures. Cytotoxicity, pH, and SCFA content of fecal water showed no differences at all among the three treatment groups. CONCLUSION: Our study revealed non-significant decreased cell proliferation and increased detoxification capacity after treatment with sulindac or VSL#3/inulin; however, combining both regimens did not show an additional effect.
机译:背景/目的:为了确定家族性腺瘤性息肉病(FAP)患者袋中腺瘤或癌的未来化学预防策略,采用(1)舒林酸,(2)菊粉/ VSL#3和( 3)在一项单中心干预研究中,对17例FAP患者进行了sulindac / inulin / VSL#3。主要终点指标为袋粘膜细胞增殖和谷胱甘肽S-转移酶(GST)解毒能力的风险参数;次要终点是粪便水的短链脂肪酸(SCFA)含量,pH和细胞毒性。方法:在每个4周的干预期开始之前和结束时,对小袋进行6次活检,并在24小时内收集粪便。在活组织检查中评估细胞增殖和GST酶活性,并在粪便水部分评估pH,SCFA含量和细胞毒性。将三种干预措施(舒林酸,菊粉/ VSL#3,舒林酸/菊粉/ VSL#3)与Mann-Whitney U检验进行了比较。结果:舒林酸或VSL#3 /菊粉后细胞增殖较低,而舒林酸/菊粉/ VSL#3联合处理则相反。舒林酸或VSL#3 /菊粉后GST酶活性增加,联合处理显示相反的效果。但是,在所有这些措施中都没有意义。在三个治疗组中,粪便水的细胞毒性,pH和SCFA含量完全没有差异。结论:我们的研究显示,舒林酸或VSL#3 /菊粉治疗后,细胞增殖和排毒能力没有明显下降;但是,两种方案的结合并没有显示出额外的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号